





Back

Nanocarriers in Neurodegenerative Disorders Therapeutic Hopes and Hypes

Nanocarriers in Neurodegenerative Disorders Therapeutic Hopes and Hypes • Book • 2024 • DOI: 10.1201/9781003383376

Mohamed, Wael

IIUM, Pahang, Kuantan, Malaysia

Show all information

↑↑ This document is one of the chapters of a book series. See all chapters

4 93th percentile

Citations ↓

3.49

FWCI ↑

Full text ∨ Export ∨ □ Save to list

Abstract

Document

Impact

Cited by (4)

Due to the lack of secure, efficient, and patient-friendly therapies for neurodegenerative disorders, there is a rising demand for innovative approaches. Despite the limited number of nanocarriers approved for human use, they have demonstrated significant potential in preclinical and, in some instances, clinical trials. In alignment with this objective, the chapters of the book are structured to offer a comprehensive overview of recent advancements in medication and dosage form development, specifically emphasizing the nanoparticulate system for targeting the brain. This book aims to furnish readers with a thorough understanding of the clinical application of nanocarrier systems for treating neurodegenerative disorders, encompassing the latest developments,

Similar documents

challenges, safety concerns, toxicity issues, regulatory considerations, prospects, and limitations. Individuals in academia, the scientific community, business, and education seeking a more effective approach to target the brain will find valuable insights in this resource. Key FeaturesProvides a comparative perspective of various nanocarrier systems, therefore facilitating the researcher's selection of appropriate nanoparticulate carriersHighlights the related restrictions of brain delivery and current available medicinesIncludes information on the advantages and disadvantages of various biomaterials utilized in the development of nanocarriers for brain targetingEmphasizes distinct facets of surface functionalization according to the brain area of interestPresents the current advances, preclinical and clinical development, and the future potential of multiple braintargeting technologies. © 2025 Taylor and Fransis Group, LLC.

Indexed keywords

Engineering controlled terms

Brain; Medical applications; Patient treatment

Engineering uncontrolled terms

Clinical application; Clinical trial; Dosage forms; Human use; Innovative approaches; Latest development; Nanocarriers; Nanoparticulate system; Neurodegenerative disorders; Safety concerns

Engineering main heading

Neurodegenerative diseases

Corresponding authors

Corresponding author

W. Mohamed

Affiliation

IIUM, Pahang, Kuantan, Malaysia

© Copyright 2025 Elsevier B.V., All rights reserved.

Abstract

Indexed keywords

Corresponding authors

About Scopus

What is Scopus

Content coverage

Scopus blog

Scopus API

Privacy matters

Language

日本語版を表示する

查看简体中文版本

查看繁體中文版本

Просмотр версии на русском языке

Customer Service

Help

Tutorials

Contact us

ELSEVIER

Terms and conditions ☐ Privacy policy ☐ Cookies settings

All content on this site: Copyright © 2025 Elsevier B.V. \nearrow , its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies \supset .

RELX™